Evidence map›Paper›PMID 24929703›Full record

ReviewTransplantation reviews (Orlando, Fla.)2014

Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Thangamani Muthukumar, John R Lee, Darshana M Dadhania, Ruchuang Ding, Vijay K Sharma, Joseph E Schwartz, Manikkam Suthanthiran

Abstract readReview
In one paragraph

Review in Transplantation reviews (Orlando, Fla.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. MicroRNAs and Transplantation.Clinics in laboratory medicine · 2019
    Review
  3. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thangamani MuthukumarDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Transplantation Medicine, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY. Electronic address: mut9002@med.cornell.edu.
John R LeeDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Transplantation Medicine, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY.
Darshana M DadhaniaDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Transplantation Medicine, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY.
Ruchuang DingDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY.
Vijay K SharmaDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY.
Joseph E SchwartzDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Psychiatry and Behavioral Science, Stony Brook School of Medicine, Stony Brook, NY.
Manikkam SuthanthiranDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY; Department of Transplantation Medicine, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY.

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
Biomolecular Markers for Safe Minimization of ImmunosuppressionR37AI051652 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SUTHANTHIRAN, MANIKKAM · 2009 to 2021
$4.7M
Clinical and Translational Science CenterKL2TR000458 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$2.1M
Biomolecular Markers of Renal Allograft StatusK08DK087824 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI MUTHUKUMAR, THANGAMANI · 2011 to 2015
$658k
NCATS NIH HHS KL2 TR000458NCATS NIH HHS KL2-TR000458NCATS NIH HHS UL1 TR000457NCRR NIH HHS UL1 RR024996NCRR NIH HHS ULI RR024996NIAID NIH HHS R37 AI051652NIAID NIH HHS R37-AI051652NIDDK NIH HHS K08 DK087824NIDDK NIH HHS K08-DK087824PHS HHS UO1A163589
6 · The paper itself

Abstract

Because the kidney allograft has the potential to function as an in-vivo flow cytometer and facilitate the access of immune cells and kidney parenchymal cells in to the urinary space, we hypothesized that mRNA profiling of urinary cells offers a noninvasive means of assessing the kidney allograft status. We overcame the inherent challenges of urinary cell mRNA profiling by developing pre-amplification protocols to compensate for low RNA yield from urinary cells and by developing robust protocols for absolute quantification mRNAs using RT-PCR assays. Armed with these tools, we undertook first single-center studies urinary cell mRNA profiling and then embarked on the multicenter Clinical Trials in Organ Transplantation-04 study of kidney transplant recipients. We report here our discovery and validation of diagnostic and prognostic biomarkers of acute cellular rejection and of interstitial fibrosis and tubular atrophy (IF/TA). Our urinary cell mRNA profiling studies, in addition to demonstrating the feasibility of accurate diagnosis of acute cellular rejection and IF/TA in the kidney allograft, advance mechanistic and potentially targetable biomarkers. Interventional trials, guided by urinary cell mRNA profiles, may lead to personalized immunosuppression in recipients of kidney allografts.

Indexed as

Kidney TransplantationAllograftsBiomarkersClinical Trials as TopicGraft RejectionHumansKidneyRNA, MessengerBiomarkersRNA, Messenger

Identifiers

PMID24929703
PMCPMC4118424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.